BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition

 
• By Joseph Haas

Bristol Myers Squibb thinks Turning Point’s ROS1/TRK inhibitor shows a best-in-class profile and potential to compete more successfully against Pfizer’s Xalkori than Roche’s Rozlytrek has.

Bristol Myers Squibb
Bristol Myers Squibb makes big precision oncology play in Turning Point buyout • Source: Bristol Myers Squibb (ROBERT BRUSCHINI IM GES LLC)

More from Deals

More from Business